2 recruiting, 1 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Pulmovant, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) Mosliciguat, Placebo, Dry Powder Inhaler - Pulmonary Hypertension, Interstitial Lung Disease | Phase 3 | Recruiting | Pulmovant, Inc. | 376 | 2026-08-31 | 2026-09-11 |
| A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD inhaled mosliciguat, Dry Powder Inhaler - Pulmonary Hypertension, Interstitial Lung Disease (ILD) | Phase 2 | Recruiting | Pulmovant, Inc. | 20 | 2025-12-23 | 2026-09-02 |
| A Phase 1 Study of Mosliciguat in Healthy, Adult Males Mosliciguat, 14C mosliciguat, Dry Powder Inhaler - Healthy Volunteer | Phase 1 | Completed | Pulmovant, Inc. | 8 | 2025-06-10 | 2026-06-16 |
| A Study of Mosliciguat in PH-ILD Mosliciguat, Dry Powder Inhaler, Placebo - Pulmonary Hypertension, Interstitial Lung Disease | Phase 2 | Active not recruiting | Pulmovant, Inc. | 135 | 2024-10-29 | 2026-09-10 |
Cardiovascular Diseases (3) · Fibrosis (3) · Hypertension, Pulmonary (3) · Lung Diseases, Interstitial (3) · Vascular Diseases (3) · Lung Diseases (2)
United States (4) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Latvia (1) · Mexico (1) · Netherlands (1) · New Zealand (1)
Ubaldo Martin (2) · Ubaldo Martin, MD (2)